|0.021 0 (0%)||12-01 15:42|
|Targets||6-month :||0.04||1-year :||0.05|
|Resists||First :||0.03||Second :||0.04|
|Supports||First :||0.02||Second :||0.01|
|MAs||MA(5) :||0.02||MA(20) :||0.02|
|MA(100) :||0.02||MA(250) :||0.18|
|MACD||MACD :||-0.1||Signal :||-0.1|
|%K %D||K(14,3) :||0||D(3) :||0|
|52-week||High :||0.52||Low :||0.02|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ ONCR ] has closed above bottom band by 43.3%. Bollinger Bands are 56.8% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 3 days. This is a sign that the current trend might continue.
|If tomorrow:||Open lower||Open higher|
|High:||0.04 - 0.04||0.04 - 0.04|
|Low:||0.02 - 0.02||0.02 - 0.02|
|Close:||0.02 - 0.02||0.02 - 0.02|
Oncorus, Inc., a clinical-stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients. The company's lead product candidate is ONCR-177, an intratumorally administered viral immunotherapy based on its oncolytic herpes simplex virus type 1 platform, which is in Phase I clinical trials for treating various cancers. It is also developing ONCR-GBM, a preclinical stage oHSV program for treating brain cancer through intratumoral injection; and synthetic viral immunotherapies based on Coxsackievirus A21 and Seneca Valley Virus. The company has a clinical trial collaboration and supply agreement with MSD International GmbH to evaluate the safety and tolerability of ONCR-177 combined with Merck's cancer immunotherapy KEYTRUDA in its Phase 1 clinical trial in patients with solid tumors. Oncorus, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Wed, 13 Sep 2023
North American Morning Briefing: Stock Futures -2- - Morningstar
Mon, 12 Jun 2023
Why Is Oncorus (ONCR) Stock Down 27% Today? - InvestorPlace
|Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
|Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
|Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
|Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
|Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
|Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
|Shares Out||26 (M)|
|Shares Float||24 (M)|
|Held by Insiders||13.4 (%)|
|Held by Institutions||41.7 (%)|
|Shares Short||448 (K)|
|Shares Short P.Month||164 (K)|
|EPS Est Next Qtrly||0|
|EPS Est This Year||0|
|EPS Est Next Year||0|
|Book Value (p.s.)||1.19|
|Profit Margin||0 %|
|Operating Margin||0 %|
|Return on Assets (ttm)||-32.3 %|
|Return on Equity (ttm)||-124.6 %|
|Qtrly Rev. Growth||0 %|
|Gross Profit (p.s.)||0|
|Sales Per Share||0|
|Qtrly Earnings Growth||0 %|
|Operating Cash Flow||-56 (M)|
|Levered Free Cash Flow||-54 (M)|
|Price to Book value||0.01|
|Price to Sales||0|
|Price to Cash Flow||-0.01|
|Dividend Pay Date||Invalid DateTime.|
|Ex-Dividend Date||Invalid DateTime.|